Oral antidiabetic drugs - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.72 [0.23, 2.24]< 10%1 study (1/-)71.4 %some concernnot evaluable moderatecrucial-
clinical improvement (28-day) 1.70 [0.52, 5.49]> 10%1 study (1/-)81.0 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.22 [0.70, 2.14]> 10%1 study (1/-)75.6 %some concernnot evaluable moderateimportant-
mechanical ventilation 1.62 [0.41, 6.39]< 10%1 study (1/-)24.6 %some concernnot evaluable moderateimportant-
ICU admission 1.96 [0.51, 7.52]< 10%1 study (1/-)16.4 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.